[HTML][HTML] Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky, P Dammann… - Cancer and Metastasis … - Springer
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
Glioma: molecular signature and crossroads with tumor microenvironment.
L Barthel, M Hadamitzky, P Dammann… - Cancer & …, 2022 - search.ebscohost.com
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
Glioma: molecular signature and crossroads with tumor microenvironment
B Lennart, M Hadamitzky, D Philipp… - Cancer and …, 2022 - search.proquest.com
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
[HTML][HTML] Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky, P Dammann… - Cancer Metastasis …, 2022 - ncbi.nlm.nih.gov
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
[PDF][PDF] Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky, P Dammann, M Schedlowski… - 2021 - researchgate.net
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
Glioma: molecular signature and crossroads with tumor microenvironment.
L Barthel, M Hadamitzky, P Dammann… - Cancer Metastasis …, 2021 - europepmc.org
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …